Carfilzomib and dexamethasone versus eight cycles of bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma : an indirect comparison using data from the phase 3 ENDEAVOR and CASTOR trials
-
Weisel, Katja (Department of Hematology. Oncology. Immunology. Rheumatology. and Pulmonology. Medical Clinic II)
;
Majer, Istvan (Amgen Europe GmbH) ;
DeCosta, Lucy (Amgen Ltd) ;
Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Goldschmidt, Hartmut (Internal Medicine V and National Center of Tumor Diseases. University Clinic Heidelberg) ;
Ludwig, Heiz (Wilhelminen Cancer Research Institute (Viena, Àustria)) ;
Campioni, Marco (Amgen Europe GmbH) ;
Szabo, Zsolt (Amgen Europe GmbH) ;
Dimopoulos, Meletios (School of Medicine. National and Kapodistrian University of Athens. Alexandra Hospital) ;
Universitat Autònoma de Barcelona